Phase Three Study Demonstrates Promising New Treatment for Cushing’s Syndrome

May 1, 2019

Study of levoketoconazole for Cushing’s syndrome shows significant improvements in acne, hirsutism in women, and peripheral edema.

The phase three SONICS study of levoketoconazole (Recorlev, Strongbridge Biopharma) for Cushing’s syndrome shows that after six months of treatment, patients experienced significant improvements in acne, hirsutism in women, and peripheral edema.

"A reduction in mean free-testosterone in women, consistent with improvements in clinical signs of hyperandrogenism was observed, and a modest increase in mean free-testosterone in men was observed.  Significant mean improvements in patient-reported quality-of-life outcomes were observed and symptoms of depression improved," the company stated in a press release.

The study was presented in a poster presentation at the American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress held in Los Angeles last week.

 

REFERENCE: Levoketoconazole In The Treatment Of Endogenous Cushing's Syndrome: Improvements In Clinical Signs And Symptoms, Patient-Reported Outcomes, And Associated Biochemical Markers In The Phase 3 Sonics Study